Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20577257 | 1.00 | HTR3A (0.41) | HTR3AMKNK1MKNK2ROCK1CDC42BPB | |
| SCHEMBL9557367 | 0.89 | MKNK1 (0.45) | MKNK1MKNK2KCNH2KDM5A | |
| SCHEMBL3723540 | 0.85 | CHRNB4 (0.37) | HTR3AMKNK1KDM5A | |
| SCHEMBL5173417 | 0.78 | — | — | |
| SCHEMBL29597773 | 0.78 | — | — | |
| SCHEMBL14868820 | 0.76 | SLC18A3 (0.42) | HTR3AHPGDS | |
| SCHEMBL29889405 | 0.76 | SLC18A3 (0.42) | HTR3AHPGDS | |
| SCHEMBL3921393 | 0.76 | SLC18A3 (0.42) | HTR3AHPGDS | |
| SCHEMBL3923917 | 0.76 | SLC18A3 (0.42) | HTR3AHPGDS | |
| SCHEMBL166955 | 0.76 | SLC18A3 (0.42) | HTR3AHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630779-B1 | ANTIBIOTIC RESISTANCE BREAKERS | KING S COLLEGE LONDON (GB) | 2025-09-03 | — | — | EP | disclosed |
| US-11746116-B2 | Antibiotic resistance breakers | KING'S COLLEGE LONDON (GB) | 2023-09-05 | — | — | US | disclosed |
| CN-110869373-B | Antibiotic resistance disruptors | 伦敦皇家学院 | 2023-03-07 | — | — | CN | disclosed |
| EP-3630779-A1 | ANTIBIOTIC RESISTANCE BREAKERS | Kings College London (GB) | 2020-04-08 | — | — | EP | disclosed |
| CN-110869373-A | Antibiotic resistance disruptors | 伦敦皇家学院 | 2020-03-06 | — | — | CN | disclosed |
| WO-2018220365-A1 | ANTIBIOTIC RESISTANCE BREAKERS | KING'S COLLEGE LONDON (GB) | 2018-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746116-B2 | Antibiotic resistance breakers | ABCC1, ARL1, AKR1C3 | HTR3A 2186/4885MKNK1 3432/4885MKNK2 4232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.